✦ LIBER ✦

Overexpression of heat shock protein 60 and the survival of blast in acute myeloid leukemia after induction therapy

✍ Scribed by Emura, I; Chou, T; Imai, Y; Kakihar, T; Ishiguro, T; Naito, M; Yoshizawa, H; Arakawa, M

Book ID: 110054632
Publisher: Nature Publishing Group
Year: 2000
Tongue: English
Weight: 97 KB
Volume: 14
Category: Article
ISSN: 0887-6924
DOI: 10.1038/sj.leu.2401857

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Overexpression of the heat-shock protein

Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia

✍ Pocaly, M; Lagarde, V; Etienne, G; Ribeil, J-A; Claverol, S; Bonneu, M; Moreau-G 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 286 KB

The prognostic significance of myelonecr

The prognostic significance of myelonecrosis after induction therapy in acute leukemia

✍ Peter A. Cassileth; John S. J. Brooks 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 313 KB 👁 2 views

Myelonecrosis is a rare antemortem finding in acute leukemia and its clinical significance is uncertain. The clinical events in nine patients with acute leukemia whose bone marrow biopsies after induction therapy revealed myelonecrosis were reviewed. No patient gained a complete remission and four p

Gemtuzumab ozogamicin, mitoxantrone, and

Gemtuzumab ozogamicin, mitoxantrone, and etoposide in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy

✍ Michael Boyiadzis; Robert L. Redner; Anastasios Raptis; Jing-Zhou Hou; Mounzer A 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 71 KB

Impact of socioeconomic status and dista

Impact of socioeconomic status and distance from treatment center on survival in patients receiving remission induction therapy for newly diagnosed acute myeloid leukemia

✍ Cristina P. Rodriguez; Rachid Baz; Rony Abou Jawde; Lisa A. Rybicki; Matt E. Kal 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 136 KB

Disease biology rather than age is the m

Disease biology rather than age is the most important determinant of survival of patients ≥ 60 years with acute myeloid leukemia treated with uniform intensive therapy

✍ Vikas Gupta; Kathy Chun; Qi-Long Yi; Mark Minden; Andre Schuh; Richard Wells; Jo 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 1 views

High-dose imatinib mesylate combined wit

High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia

✍ Rea, D; Legros, L; Raffoux, E; Thomas, X; Turlure, P; Maury, S; Dupriez, B; Pign 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 100 KB